AbCellera Biologics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-20.3%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$0.66next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release & ABCL635 Phase 2 Data Drop | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Partner-led programs with downstreams Quarterly40.0
Molecules in the clinic with downstreams Quarterly14.0
Total available liquidity Quarterly655M
Watch Items
- ABCL635 Phase 2 clinical trial readout in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS)Trigger: Efficacy and safety results comparable to small-molecule NK3R antagonists with a cleaner safety profile and once-monthly dosing potentialAction: Evaluate late-stage development strategy and prepare for Phase 3 regulatory engagement in 2027
- ABCL575 Phase 1 clinical trial progressionTrigger: Top-line Phase 1 data readout expected in Q4 2026Action: Assess safety and pharmacokinetic profile to determine Phase 2 trial design
- IND-enabling activities for ABCL688 and ABCL386Trigger: Successful IND/CTA filings to enter the clinic by the end of 2027Action: Monitor preclinical safety, toxicology, and manufacturing readiness
Research as of 19 Jun 2026